Movement Alert｜GENSCRIPT BIO Rises 7.9% in Regular Trading, Lilly TuneLab Collaboration and JPMorgan Stake Increase Fuel Rally

Market Focus09:31

On September 18, GENSCRIPT BIO rose 7.9% in regular trading, trading at HK$39.52/share, with turnover of HK$166 million. The stock continued its strong upward momentum following a surge of over 16% in the prior session.

On the news front, the company announced a collaboration agreement with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab. Under the agreement, GENSCRIPT BIO will provide wet lab services at preferential rates to TuneLab participating enterprises, helping translate AI predictions into biological evidence data and accelerating candidate drug evaluation. The board stated this move further expands the company's footprint in the AI-driven drug discovery ecosystem.

The rally is further supported by JPMorgan's significant stake increase of approximately 16.72 million shares at HK$32.02 per share, totaling about HK$535 million, lifting its position to 7.48%. JPMorgan reiterated an Overweight rating with a HK$41 target price, citing sustained AIDD order momentum. Additionally, the company reported robust H1 results with revenue of US$404 million, up 27.3% year-over-year, and adjusted net profit of US$62.5 million, surging 203.3%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120790220?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-18 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120790220","market":"hk","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 7.9% in Regular Trading, Lilly TuneLab Collaboration and JPMorgan Stake Increase Fuel Rally","media":"Market Focus","content":"<p><p>On September 18, GENSCRIPT BIO rose 7.9% in regular trading, trading at HK$39.52/share, with turnover of HK$166 million. The stock continued its strong upward momentum following a surge of over 16% in the prior session.</p><p>On the news front, the company announced a collaboration agreement with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab. Under the agreement, GENSCRIPT BIO will provide wet lab services at preferential rates to TuneLab participating enterprises, helping translate AI predictions into biological evidence data and accelerating candidate drug evaluation. The board stated this move further expands the company's footprint in the AI-driven drug discovery ecosystem.</p><p>The rally is further supported by JPMorgan's significant stake increase of approximately 16.72 million shares at HK$32.02 per share, totaling about HK$535 million, lifting its position to 7.48%. JPMorgan reiterated an Overweight rating with a HK$41 target price, citing sustained AIDD order momentum. Additionally, the company reported robust H1 results with revenue of US$404 million, up 27.3% year-over-year, and adjusted net profit of US$62.5 million, surging 203.3%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 7.9% in Regular Trading, Lilly TuneLab Collaboration and JPMorgan Stake Increase Fuel Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 7.9% in Regular Trading, Lilly TuneLab Collaboration and JPMorgan Stake Increase Fuel Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-18 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 18, GENSCRIPT BIO rose 7.9% in regular trading, trading at HK$39.52/share, with turnover of HK$166 million. The stock continued its strong upward momentum following a surge of over 16% in the prior session.</p><p>On the news front, the company announced a collaboration agreement with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab. Under the agreement, GENSCRIPT BIO will provide wet lab services at preferential rates to TuneLab participating enterprises, helping translate AI predictions into biological evidence data and accelerating candidate drug evaluation. The board stated this move further expands the company's footprint in the AI-driven drug discovery ecosystem.</p><p>The rally is further supported by JPMorgan's significant stake increase of approximately 16.72 million shares at HK$32.02 per share, totaling about HK$535 million, lifting its position to 7.48%. JPMorgan reiterated an Overweight rating with a HK$41 target price, citing sustained AIDD order momentum. Additionally, the company reported robust H1 results with revenue of US$404 million, up 27.3% year-over-year, and adjusted net profit of US$62.5 million, surging 203.3%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1120790220","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120790220","pubTimestamp":1789695091,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 18, GENSCRIPT BIO rose 7.9% in regular trading, trading at HK$39.52/share, with turnover of HK$166 million. The stock continued its strong upward momentum following a surge of over 16%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势警报|金斯瑞生物在常规交易中上涨 7.9%，礼来 TuneLab 合作和摩根大通增持推动反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On September 18, GENSCRIPT BIO rose 7.9% in regular trading, trading at HK$39.52/share, with turnover of HK$166 million. The stock continued its strong upward momentum following a surge of over 16% in the prior session.On the news front, the company announced a collaboration agreement with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab. Under the agreement, GENSCRIPT BIO will provide wet lab services at preferential rates to TuneLab participating enterprises, helping translate AI predictions into biological evidence data and accelerating candidate drug evaluation. The board stated this move further expands the company's footprint in the AI-driven drug discovery ecosystem.The rally is further supported by JPMorgan's significant stake increase of approximately 16.72 million shares at HK$32.02 per share, totaling about HK$535 million, lifting its position to 7.48%. JPMorgan reiterated an Overweight rating with a HK$41 target price, citing sustained AIDD order momentum. Additionally, the company reported robust H1 results with revenue of US$404 million, up 27.3% year-over-year, and adjusted net profit of US$62.5 million, surging 203.3%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120790220","isCrawlerRequest":true}